Published in Nat Rev Cancer on February 01, 2014
Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature (2015) 3.64
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell (2015) 2.48
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell (2016) 2.27
Chemical tagging and customizing of cellular chromatin states using ultrafast trans-splicing inteins. Nat Chem (2015) 2.17
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A (2015) 1.29
Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. Bioinformatics (2014) 1.20
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer (2015) 1.15
MethPed: a DNA methylation classifier tool for the identification of pediatric brain tumor subtypes. Clin Epigenetics (2015) 1.15
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer (2014) 1.10
Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. J Clin Oncol (2015) 1.02
Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol (2017) 0.99
From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget (2015) 0.96
Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res (2014) 0.96
Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proc Natl Acad Sci U S A (2014) 0.95
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell (2016) 0.92
Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol (2016) 0.91
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell (2015) 0.91
Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells (2014) 0.87
Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol (2014) 0.87
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. Front Oncol (2015) 0.86
A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics Chromatin (2014) 0.85
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84
ACVR1 mutations in DIPG: lessons learned from FOP. Cancer Res (2014) 0.84
Integrative bayesian network analysis of genomic data. Cancer Inform (2014) 0.83
Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J (2014) 0.83
Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme. Oncotarget (2016) 0.83
Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy. Neuro Oncol (2015) 0.82
CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. Oncotarget (2015) 0.82
Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol (2016) 0.82
USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. Neuro Oncol (2015) 0.81
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci (2015) 0.81
miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res (2016) 0.81
The genetic signatures of pediatric high-grade glioma: no longer a one-act play. Semin Radiat Oncol (2014) 0.80
Glioblastomas Require Integrin αvβ3/PAK4 Signaling to Escape Senescence. Cancer Res (2015) 0.80
Mutations in chromatin machinery and pediatric high-grade glioma. Sci Adv (2016) 0.80
KIAA0247 suppresses the proliferation, angiogenesis and promote apoptosis of human glioma through inactivation of the AKT and Stat3 signaling pathway. Oncotarget (2016) 0.80
Management of high-grade gliomas in the pediatric patient: Past, present, and future. Neurooncol Pract (2014) 0.80
Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma. Clin Epigenetics (2015) 0.80
Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) (2016) 0.79
Taspase1: a 'misunderstood' protease with translational cancer relevance. Oncogene (2015) 0.78
EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas. Epigenetics (2015) 0.78
Molecular characteristics of pediatric high-grade gliomas. CNS Oncol (2014) 0.78
Pediatric gliomas as neurodevelopmental disorders. Glia (2015) 0.77
Comparative transcriptomics reveals similarities and differences between astrocytoma grades. BMC Cancer (2015) 0.77
Glioblastoma, hypoxia and autophagy: a survival-prone 'ménage-à-trois'. Cell Death Dis (2016) 0.77
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest (2015) 0.77
DCVax®-L--developed by Northwest Biotherapeutics. Hum Vaccin Immunother (2014) 0.76
Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathol (2014) 0.76
Extracellular Vesicles in Brain Tumor Progression. Cell Mol Neurobiol (2016) 0.76
Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. PLoS One (2015) 0.76
G-DOC Plus - an integrative bioinformatics platform for precision medicine. BMC Bioinformatics (2016) 0.76
The Fallacy of Univariate Solutions to Complex Systems Problems. Front Neurosci (2016) 0.75
Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes (Basel) (2017) 0.75
Chronophin is a glial tumor modifier involved in the regulation of glioblastoma growth and invasiveness. Oncogene (2015) 0.75
Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas. Neurotherapeutics (2017) 0.75
Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas. Curr Neuropharmacol (2017) 0.75
Spatial heterogeneity in medulloblastoma. Nat Genet (2017) 0.75
Emx2 as a novel tool to suppress glioblastoma. Oncotarget (2016) 0.75
The promise of molecular profiling of choroid plexus tumors for diagnostic and prognostic stratification: where to go from here? Neuro Oncol (2016) 0.75
Protein interacting with C kinase 1 suppresses invasion and anchorage-independent growth of astrocytic tumor cells. Mol Biol Cell (2015) 0.75
Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. J Neurooncol (2014) 0.75
Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget (2016) 0.75
PTEN signaling in the postnatal perivascular progenitor niche drives medulloblastoma formation. Cancer Res (2016) 0.75
Copy Number Profiling of Brazilian Astrocytomas. G3 (Bethesda) (2016) 0.75
Importance of rare gene copy number alterations for personalized tumor characterization and survival analysis. Genome Biol (2016) 0.75
Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model. Int J Nanomedicine (2017) 0.75
Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. Viruses (2016) 0.75
Commentary on: "A Multi-Institutional Experience in Pediatric High Grade Glioma". Front Oncol (2015) 0.75
Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. Mol Imaging (2017) 0.75
Pediatric glioblastoma: a single institution experience. Childs Nerv Syst (2015) 0.75
Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int J Nanomedicine (2017) 0.75
G protein-coupled receptor kinase 6 is overexpressed in glioma and promotes glioma cell proliferation. Oncotarget (2017) 0.75
Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther (2017) 0.75
Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. Neoplasia (2017) 0.75
Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther (2017) 0.75
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. PLoS One (2017) 0.75
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell (2017) 0.75
High-grade glioma in very young children: a rare and particular patient population. Oncotarget (2017) 0.75
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci (2017) 0.75
MicroRNA-96 Regulates Apoptosis by Targeting PDCD4 in Human Glioma Cells. Technol Cancer Res Treat (2016) 0.75
Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Clonal evolution in cancer. Nature (2012) 11.07
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Cancer stem cells. N Engl J Med (2006) 9.63
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Spatio-temporal transcriptome of the human brain. Nature (2011) 9.19
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
The transcriptional network for mesenchymal transformation of brain tumours. Nature (2009) 8.44
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol (2012) 8.16
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 6.29
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 5.71
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep (2011) 4.89
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 4.78
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science (2012) 4.14
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 4.00
Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res (2008) 3.99
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol (2009) 3.99
Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet (2000) 3.98
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
The definition of primary and secondary glioblastoma. Clin Cancer Res (2012) 3.84
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell (2012) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol (2006) 3.68
A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev (1998) 3.68
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol (2010) 3.51
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 3.27
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res (2009) 3.22
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 2.98
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell (2013) 2.87
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol (2012) 2.87
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev (2013) 2.86
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol (2009) 2.65
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 2.50
Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell (2012) 2.50
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44